Key Highlights
- Paul Davie joins X-Chem as Chief Business Officer.
- Davie brings extensive experience from Schrödinger.
- Focus on strategic partnerships and new market opportunities.
- X-Chem’s platform combines DEL screening with AI-driven informatics.
- Innovative solutions for accelerated drug discovery.
Source: Business Wire
Notable Quotes
- “To deliver on our strategy of using our market-leading digital and experimental drug discovery platforms, the right strategic partnerships are essential. I’m excited that Paul — with his deep expertise and strong global network — joins us as our platforms continue evolving with new capabilities that enable our partners to achieve discovery program success.” — Karen Lackey, Chief Executive Officer at X-Chem
- “I am thrilled to join the X-Chem team and help deliver on its ambitious plans. The combination of the world’s leading DEL hit-finding platform, hugely skilled medicinal chemistry teams and powerful AI-driven informatics capabilities singularly positions X-Chem as an outstanding partner for cost-effective drug discovery acceleration.” — Paul Davie, Chief Business Officer at X-Chem, Inc
SoHC's Take
X-Chem’s strategic appointment of Paul Davie as Chief Business Officer underscores the company’s commitment to enhancing its global reach and innovative drug discovery capabilities. Davie’s track record at Schrödinger in driving business growth through strategic partnerships is a testament to his ability to navigate complex markets and deliver substantial value. As X-Chem continues to integrate AI-driven informatics with its pioneering DEL technology, the expertise Davie brings will be pivotal in expanding the company’s footprint and achieving new milestones in drug discovery acceleration.
